M&A Deal Summary

Novo Holdings A/S Acquires Xellia Pharmaceuticals AS

On May 21, 2013, corporate investor Novo Holdings A/S acquired life science company Xellia Pharmaceuticals AS from 3i Private Equity for 700M USD

Acquisition Highlights
  • This is Novo Holdings A/S’s 1st transaction in the Life Science sector.
  • This is Novo Holdings A/S’s 1st largest (disclosed) transaction.
  • This is Novo Holdings A/S’s 1st transaction in Norway.

M&A Deal Summary

Date 2013-05-21
Target Xellia Pharmaceuticals AS
Sector Life Science
Buyer(s) Novo Holdings A/S
Sellers(s) 3i Private Equity
Deal Type Secondary Buyout
Deal Value 700M USD

Target

Xellia Pharmaceuticals AS

Oslo, Norway
website
Xellia is a provider and developer of anti-infective drugs, in active pharmaceutical ingredient (API) and final dosage presentation. The business employs over 800 staff and serves over 600 customers in 60 countries. Its clients include a range of national, multinational and global pharmaceutical and generics companies.

Search 159,180 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novo Holdings A/S

Investor Investor Investor Investor Investor

website


Category Corporate Investor
Founded 1999
SizeMiddle-Market
Type Sector Agnostic
DESCRIPTION

Novo Holdings A/S is a Danish holding company and the investment arm of the Novo Nordisk Foundation. Novo Holdings' objective is to grow the assets of the Foundation and improve the lives of people around the world. In addition to investing in equity and fixed income securities, Novo Holdings pursues direct investments in life science companies. Novo Holdings A/S was established in 1999 and is headquartered in Hellerup, Denmark.


DEAL STATS #
Overall 1 of 7
Sector (Life Science) 1 of 3
Type (Secondary Buyout) 1 of 5
Country (Norway) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-15 Sonion A/S

Roskilde, Denmark

Sonion is a development, manufacturing and sale of advanced micro acoustical and micro mechanical components and solutions. The company is a B2B provider for global manufacturers of hearing instruments, mobile handsets, headsets, earphones, and medical devices.

Buy -

Seller(S) 1

SELLER

3i Private Equity

London, United Kingdom

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 1945
PE ASSETS 11.0B GBP
SizeMega
Type Sector Agnostic
DESCRIPTION

3i Private Equity is the private equity arm of 3i Group, a publicly held, global investment firm focused on private equity and infrastructure investing. 3i Private Equity generally targets buyout and growth capital financings and looks for opportunities across Europe, North America, and Asia. The Firm's targeted transaction range is €100 to €500 million. Industries of interest include business services, healthcare, consumer, media, oil/gas & power, technology, and financial services. 3i Group was originally formed in 1945 and is based in London.


DEAL STATS #
Overall 143 of 186
Sector (Life Science) 3 of 4
Type (Secondary Buyout) 61 of 80
Country (Norway) 4 of 4
Year (2013) 11 of 17
Size (of disclosed) 12 of 74
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-05-14 HTC Group AB

Soderkoping, Sweden

HTC Group AB is a developer and manufacturer of professional floor grinding systems and floor solutions.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-05-29 Franklin Offshore International Pte. Ltd.

Singapore

Franklin is the provider of rigging, lifting and mooring services to the offshore and marine industries in South East Asia.

Sell -